Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been newly diagnosed with classical Hodgkin lymphoma at stage IIB, III, or IV, confirmed by a tissue biopsy, and who have not yet received any treatment for this condition
- People whose disease extent has been assessed using a whole-body PET/CT scan (a type of imaging scan)
- People between the ages of 18 and 60 years
- People whose general physical functioning meets a certain level, meaning they are able to carry out at least some daily activities (ECOG score of 0–2; confirm with trial site for details)
- People who are willing and able to use highly effective birth control methods from the time of signing the consent form, throughout the study, and for 6 months after the last dose of the study drug
Who may not be able to join:
- People with serious kidney, liver, or bile-processing problems beyond certain measured levels (confirm with trial site for the specific values)
- People who have significant breathing difficulties at the time of joining the trial
- People who need medication to maintain their blood pressure at the time of joining
- People who have a bacterial or fungal infection that is not under control at the time of joining
- People who have an active autoimmune disease (where the immune system attacks the body) or have a history of one that required ongoing medical treatment
- People who are pregnant, breastfeeding, or planning to become pregnant or father a child during the study period
- People who have a known allergy or sensitivity to any of the study drugs
- People who have a physical or mental health condition that would prevent them from taking part in study procedures, including being able to sign a consent form
- People who are currently taking part in another clinical trial involving other study drugs or medical devices
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Natalia Mikhailova, MD, PhD, St. Petersburg State Pavlov Medical University
Phone: +78123386265
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.